# US 2017/0281801 A1 · Psma-targeted nir dyes and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281801 A1
- Document ID: US20170281801A1
- Status: Published application
- Kind: A1
- Application number: 15/623,353
- Filed: 2017-06-14
- Published: 2017-10-05
- Earliest claimed: 2015-09-09
- Assignees: On Target Laboratories, LLC
- Applicants: On Target Laboratories, LLC
- Inventors: Sumith A. Kularatne; Pravin Gagare
- Web page: https://patentgrep.com/patent/US20170281801A1

## CPC

- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 13/08: of the prostate
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/0606: {the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr}
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/06095: {Arg-amino acid}
- C07K 5/06121: {the second amino acid being aromatic or cycloaliphatic}
- C07K 5/06147: {and His-amino acid; Derivatives thereof}
- C07K 5/06156: {and Trp-amino acid; Derivatives thereof}
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07K 5/0817: {the first amino acid being Arg}
- C07K 5/1019: {with the first amino acid being basic}
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 7/06: having 5 to 11 amino acids
- C09B 23/0066: {the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 33/57555: of the prostate
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 49/0017: {Fluorescence in vivo}
- A61K 49/0034: {Indocyanine green, i.e. ICG, cardiogreen}
- A61K 49/16: Antibodies; Immunoglobulins; Fragments thereof
- C12Y 304/17021: Glutamate carboxypeptidase II (3.4.17.21)
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- G01N 2333/948: acting on peptide bonds (3.4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

## Claims

### Claim 1

A compound having a formula: B-X-Y-Z, wherein
B comprises a compound capable of binding to prostate specific membrane antigen (PSMA),
X is EAOA,
Y comprises at least one amino acid, or derivative thereof, and
Z comprises a near-infra red (NIR) dye.

### Claim 2 (depends on 1)

The compound of claim 1, wherein B is selected from the group consisting of a small molecule, ligand, inhibitor, agonist, and a derivative thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein B is 2-[3-(1,3-dicarboxypropyl)-ureido]pentanedioic acid (DUPA) or derivative thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Y comprises negatively charged amino acids.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Y comprises positively charged amino acids.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Y comprises aromatic amino acids.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Z has a positive charge.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Z has a negative charge.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Z is selected from the group consisting of LS288, IR800, SP054, S0121, KODAK, S2076, S0456,

### Claim 10

A compound having a formula: B-X-Y-Z, wherein
B comprises DUPA or a derivative thereof;
X is EAOA,
Y is selected from the group consisting of phenylalanine-tyrosine, histidine-tyrosine, phenylalanine-arginine-tyrosine, and histidine-tyrosine;
and Z comprises S0456.

### Claim 11

A compound having a structural formula:
or a pharmaceutically acceptable salt thereof, or isotopes thereof, wherein:
R1 represents a hydrogen or SO3H;
R2 represents a hydrogen, or CH3, or C3H6SO3−, or C3H6SO3H or C4H8SO3−, or C4H8SO3H or C3H6N+(CH3)3;
R3, and R5 each represents a carbon, optionally one or more sharing bonds, or oxygen, or sulfur, or nitrogen
R4 represents a carbon with optionally one or more sharing bonds;
R6 represents nitrogen, oxygen, or sulfur or no atom (direct C—C bond between aromatic ring and vinyl ring);
R7 is optional and when present represents electron donating aromatic substitution group;
R8 is optional and when present represents linkers with aromatic amino acids such as Phe, Trp, His, Tyr, or derivative of them, and/or cationic amino acids such Arg, Lys, or derivative of them, and/or anionic amino acids such as Asp, Glu or derivative of them, and/or unnatural amino acids of aromatic/cationic/anionic acids or derivative;
R9 represents EAOA, or derivative thereof
R10 represents a CO2H, PO3H2, SO3H, CH2SO3H, CH2CONHCH2SO3H, CH2CONHCH2CH2SO3H;
R11 represents CO2H, SO3H, CH2CONHCH2SO3H, CH2CONHCH2CH2SO3H; and
R12 represents independently represents a hydrogen, a methyl group, CH2COOH, a CH2 and may optionally represent each a CH2 sharing a bond.

### Claim 12 (depends on 11)

The compound of claim 11 wherein said compound is selected from the group consisting of:

### Claim 13 (depends on 1)

The compound of claim 1 wherein the amino acid incudes an oxygen-containing side chain group.

### Claim 14 (depends on 13)

The compound of claim 13 wherein the amino acid including an oxygen-containing side chain group is selected from the group consisting of phenylalanine-tyrosine, phenylalanine-serine, and phenylalanine-tyramine.

### Claim 15 (depends on 13)

The compound of claim 13 wherein the amino acid including an oxygen-containing side chain group is phenylalanine-tyrosine.

### Claim 16 (depends on 1)

The compound of claim 1 wherein the amino acid incudes a sulfur-containing side chain group.

### Claim 17 (depends on 16)

The compound of claim 16 wherein the amino acid including a sulfur-containing side chain group is selected from the group consisting of phenylalanine-cysteine, phenylalanine-methionine, phenylalanine-selenocyseteine, or histidine-cysteine.

### Claim 18 (depends on 16)

The compound of claim 16 wherein the amino acid including a sulfur-containing side chain group is phenylalanine-cysteine.

### Claim 19 (depends on 1)

The compound of claim 1 wherein the amino acid incudes a nitrogen-containing side chain group.

### Claim 20 (depends on 19)

The compound of claim 19 wherein the amino acid including a nitrogen-containing side chain group is selected from the group consisting of phenylalanine-lysine, phenylalanine-ornithine, phenylalanine-arginine, or histidine-lysine.

### Claim 21 (depends on 19)

The compound of claim 19 wherein the amino acid including a nitrogen.

### Claim 22 (depends on 1)

The compound of claim 1 wherein the amino acid is selected from the group consisting of tyrosine, cysteine, lysine or a derivative thereof, or phenylalanine-tyrosine, phenylalanine-cysteine, phenylalanine-lysine, histidine-tyrosine, phenylalanine-serine, phenylalanine-tyramine, phenylalanine-methionine, phenylalanine-selenocyseteine, histidine-cysteine, phenylalanine-ornithine, phenylalanine-arginine, and histidine-lysine and_derivatives thereof.

### Claim 23 (depends on 1)

The compound of claim 1 wherein Y comprises a phenylalanine-tyrosine or derivative thereof.

### Claim 24 (depends on 1)

The compound of claim 1 wherein Y comprises an isotope of amino acids or derivative thereof.

### Claim 25 (depends on 24)

The compound of claim 24 wherein a carbon isotope is on an aromatic ring of tyrosine or phenylalanine.

### Claim 26 (depends on 24)

The compound of claim 24 wherein a hydrogen isotope is a substituent of an aromatic ring of tyrosine or phenylalanine.

### Claim 27

A compound having a formula: B-X-Y-Z, wherein
B comprises a compound capable of binding to prostate specific membrane antigen (PSMA),
X is EAOA,
Y comprises at least one amino acid or derivative thereof, wherein the amino acid derivative is a derivative of tyrosine selected from the group consisting of:
or racemic mixtures thereof, and
Z comprises a near-infra red (NIR) dye.

### Claim 28 (depends on 1)

The compound of claim 1 wherein the compound has an absorption and emission maxima between about 500 nm and about 900 nm.

### Claim 29 (depends on 28)

The compound of claim 28, wherein the compound has an absorption and emission maxima between about 600 nm and 800 nm.

### Claim 30 (depends on 1)

The compound of claim 1, wherein the compound is made to fluoresce after distribution thereof in tissue cells.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the tissue cells are selected from the group consisting of prostate cells, prostate cancer cells, bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells and melanoma cells.

### Claim 32 (depends on 10)

The compound of claim 10 wherein the compound has an absorption and emission maxima between about 500 nm and about 900 nm.

### Claim 33 (depends on 27)

The compound of claim 27 wherein the compound has an absorption and emission maxima between about 500 nm and about 900 nm.

### Claim 34 (depends on 10)

The compound of claim 10 wherein the compound is made to fluoresce after distribution thereof in tissue cells.

### Claim 35 (depends on 27)

The compound of claim 27 wherein the compound is made to fluoresce after distribution thereof in tissue cells.

### Claim 36 (depends on 34)

The compound of claim 34, wherein the tissue cells are selected from the group consisting of prostate cells, prostate cancer cells, bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells and melanoma cells.

### Claim 37 (depends on 35)

The compound of claim 35, wherein the tissue cells are selected from the group consisting of prostate cells, prostate cancer cells, bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells and melanoma cells.

### Claim 38 (depends on 1)

The compound of claim 1, wherein the compound is made to fluoresce by subjecting the compound to excitation light of near infrared wavelength.

### Claim 39 (depends on 1)

The compound of claim 1, wherein the compound has a binding affinity to PSMA that is similar to the binding affinity of DUPA.

### Claim 40 (depends on 1)

The compound of claim 1, wherein the compound is highly selective for targeting to a tumor cell.

### Claim 41 (depends on 1)

A composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 42 (depends on 1)

A method of optical imaging of a biological tissue that expresses PSMA, the method comprising:
(a) contacting the biological tissue with a composition of claim 1,
(b) allowing time for the compound in the composition to distribute within a biological target;
(c) illuminating the tissue with an excitation light of a wavelength absorbable by the compound; and
(d) detecting an optical signal emitted by the compound.

### Claim 43 (depends on 42)

The method of claim 42, wherein an optical signal emitted by the compound is used to construct an image.

### Claim 44 (depends on 42)

The method of claim 42, wherein the biological tissue is selected from the group consisting of prostate cells, prostate cancer cells, bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells and melanoma cells.

### Claim 45 (depends on 10)

A method of optical imaging of a biological tissue that expresses PSMA, the method comprising:
(a) contacting the biological tissue with a composition of claim 10,
(b) allowing time for the compound in the composition to distribute within a biological target;
(c) illuminating the tissue with an excitation light of a wavelength absorbable by the compound; and
(d) detecting an optical signal emitted by the compound.

### Claim 46 (depends on 45)

The method of claim 45, wherein the optical signal emitted by the compound is used to construct an image.

### Claim 47 (depends on 45)

The method of claim 45, wherein the biological tissue is selected from the group consisting of prostate cells, prostate cancer cells, bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells and melanoma cells.

### Claim 48 (depends on 27)

A method of optical imaging of a biological tissue that expresses PSMA, the method comprising:
(a) contacting the biological tissue with a composition of claim 27,
(b) allowing time for the compound in the composition to distribute within the biological target;
(c) illuminating the tissue with an excitation light of a wavelength absorbable by the compound; and
(d) detecting an optical signal emitted by the compound.

### Claim 49 (depends on 48)

The method of claim 48, wherein the optical signal emitted by the compound is used to construct an image.

### Claim 50 (depends on 48)

The method of claim 48, wherein the biological tissue is selected from the group consisting of prostate cells, prostate cancer cells, bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells and melanoma cells.

### Claim 51 (depends on 1)

A method of identifying a target cell type in a biological sample comprising:
a) contacting the biological sample with a compound of claim 1 for a time and under conditions that allow for binding of the compound to at least one cell of the target cell type or vasculature of target tissue; and
b) optically detecting presence or absence of the compound of in the biological sample, wherein presence of the compound in detecting step b) indicates that the target cell type is present in the biological sample.

### Claim 52 (depends on 10)

A method of identifying a target cell type in a biological sample comprising
a) contacting the biological sample with a compound of claim 10 for a time and under conditions that allow for binding of the compound to at least one cell of the target cell type; and
b) optically detecting presence or absence of the compound of in the biological sample,
c) wherein presence of the compound in detecting step b) indicates that the target cell type is present in the biological sample.

### Claim 53 (depends on 27)

A method of identifying a target cell type in a biological sample comprising
a) contacting the biological sample with a compound of claim 27 for a time and under conditions that allow for binding of the compound to at least one cell of the target cell type; and
b) optically detecting presence or absence of the compound of in the biological sample,
c) wherein presence of the compound in detecting step b) indicates that the target cell type is present in the biological sample.

### Claim 54 (depends on 1)

A kit comprising a compound of claim 1.

### Claim 55 (depends on 1)

The compound of claim 1 wherein X has a length of 7 atoms to 14 atoms.

### Claim 56 (depends on 10)

The compound of claim 10 wherein X has a length of 7 atoms to 14 atoms.

### Claim 57 (depends on 27)

The compound of claim 27 wherein X has a length of 7 atoms to 14 atoms.

### Claim 58 (depends on 11)

The compound of claim 11 wherein R9 has a length of 7 atoms to 14 atoms.

### Claim 59 (depends on 42)

The method of claim 42, wherein the optical signal is detected using an endoscope, catheter, tomographic system, hand-held optical imaging system, surgical goggles, or intra-operative microscope.

### Claim 60 (depends on 45)

The method of claim 45, wherein the optical signal is detected using an endoscope, catheter, tomographic system, hand-held optical imaging system, surgical goggles, or intra-operative microscope.

### Claim 61 (depends on 48)

The method of claim 48, wherein the optical signal is detected using an endoscope, catheter, tomographic system, hand-held optical imaging system, surgical goggles, or intra-operative microscope.
